CN Patent

CN105407906A — 预防或治疗巴斯综合征的方法和组合物

Assigned to Kant Biomedical Co ltd · Expires 2016-03-16 · 10y expired

What this patent protects

本公开内容提供预防或治疗在哺乳动物受试者中的巴斯综合征、降低与巴斯综合征相关的危险因子和/或降低巴斯综合征的可能性或严重性的方法。所述方法包括向受检者施用有效量的芳族阳离子肽以增加在有此需要的受试者中的TAZ1表达。

USPTO Abstract

本公开内容提供预防或治疗在哺乳动物受试者中的巴斯综合征、降低与巴斯综合征相关的危险因子和/或降低巴斯综合征的可能性或严重性的方法。所述方法包括向受检者施用有效量的芳族阳离子肽以增加在有此需要的受试者中的TAZ1表达。

Drugs covered by this patent

elamipretide-hydrochloride (ELAMIPRETIDE HYDROCHLORIDE)

Patent Metadata

Patent number: CN105407906A
Jurisdiction: CN
Classification: —
Expires: 2016-03-16
Drug substance claim: No
Drug product claim: No
Assignee: Kant Biomedical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.